Clinical significance of oral immune therapy with colostrum on reducing incidence of nosocomial infection in very low birth weight preterm infants

doi:10.3877/cma.j.issn.1673-5250.2019.05.009

Objective

To investigate the effect of oral immune therapy with colostrum on reducing incidence of nosocomial infection in very low birth weight (VLBW) preterm infants.

Methods

A total of 198 VLBW preterm infants who were hospitalized in neonatal intensive care unit (NICU) of the Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University from May 2016 to April 2018, were enrolled as research subjects. They were divided into observation group (n=108, treated by oral immune therapy with colostrum) and control group (n=98, treated by equal amount of normal saline to replacing colostrum) based on informed consent and offer colostrum or not within the first 72 h after VLBW preterm infants birth. The independent-samples t test and chi-square test were used to compare the clinical data, incidence rate of nosocomial infection and clinical outcomes between two groups of patients. This study was reviewed by the Ethics Committee of the Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University (Approval No. 2018-06-0328-02). Informed consents were obtained from the guardians or entrusted agents of all infants.

Results

①There were no significant differences between two groups of VLBW preterm infants in gestational age, birth weight, proportion of small for gestational age, head circumference, constituent ratio of gender and delivery mode, incidence rate of time of premature rupture of membranes >18 h, usage of prenatal antibacterials in mother, incidence rate of asphyxia of infants, time of parenteral nutrition, proportion of twins and incidence rate of patent ductus arteriosus (P>0.05). The rate of central venous catheterization and mechanical ventilation were 38.9% and 32.4% in observation group, which were higher than those of 25.6% and 14.4% in control group, and the differences were statistically significant (χ²=3.958, P=0.047; χ²=8.625, P=0.003). ②The total incidence rate of nosocomial infection and clinical sepsis were 21.3% and 13.0% in observation group, which were lower than those of 34.4% and 25.6% in control group, and the differences were statistically significant (χ²=4.279, P=0.039; χ²=5.123, P=0.024). There were no significant differences between two groups in the incidence rates of proven sepsis, ventilator associated pneumonia (VAP) and urinary tract infection (P>0.05). ③There were no significant differences between two groups in length of hospital stay, head circumference and weight on the day of discharge, and discharge rate of improved disease conditions (P>0.05).

Conclusions

Oral immune therapy with colostrum can reduce the incidence of nosocomial infection in VLBW preterm infants.

Key words: Cross infection, Immunotherapy, Colostrum, Intensive care units, neonatal, Pneumonia, ventilator-associated, Infant, very low birth weight, Infant, premature

表1 2组患儿临床资料比较

组别	例数	胎龄(周，±s)	出生体重(g, ±s)	小于胎龄儿[例数(%)]	头围(cm，±s)	性别[例数(%)]		母亲分娩方式[例数(%)]
组别	例数	胎龄(周，±s)	出生体重(g, ±s)	小于胎龄儿[例数(%)]	头围(cm，±s)	男	女	阴道分娩	剖宫产
观察组	108	30.0±1.8	1 239±189	38(35.2)	27.4±1.8	59(54.6)	49(45.4)	45(41.7)	63(58.3)
对照组	90	29.7±1.7	1 261±188	21(23.3)	27.5±1.8	42(46.7)	48(53.3)	46(51.1)	44(48.9)
检验值	?	t＝－1.380	t＝0.832	χ²＝3.296	t＝0.114	χ²＝1.246		χ²＝1.763
P值	?	0.169	0.407	0.069	0.910	0.264		0.184
组别	例数	母亲胎膜早破>18 h[例数(%)]	母亲产前使用抗菌药物[例数(%)]	窒息[例数(%)]	中心静脉置管[例数(%)]	机械通气治疗[例数(%)]	静脉营养时间[d，M(P₂₅～P₇₅)]	双胎[例数(%)]	动脉导管未闭[例数(%)]
观察组	108	41(38.3)	33(30.6)	64(59.3)	42(38.9)	35(32.4)	14.0(10.0～20.0)	39(36.1)	59(54.6)
对照组	90	43(47.8)	31(34.4)	59(65.6)	23(25.6)	13(14.4)	13.0(9.8～20.0)	38(42.2)	46(51.1)
检验值	?	χ²＝1.789	χ²＝2.739	χ²＝0.827	χ²＝3.958	χ²＝8.625	Z＝－0.730	χ²＝0.771	χ²＝0.244
P值	?	0.181	0.254	0.363	0.047	0.003	0.466	0.380	0.621

表1 2组患儿临床资料比较

组别	例数	胎龄(周，±s)	出生体重(g, ±s)	小于胎龄儿[例数(%)]	头围(cm，±s)	性别[例数(%)]		母亲分娩方式[例数(%)]
组别	例数	胎龄(周，±s)	出生体重(g, ±s)	小于胎龄儿[例数(%)]	头围(cm，±s)	男	女	阴道分娩	剖宫产
观察组	108	30.0±1.8	1 239±189	38(35.2)	27.4±1.8	59(54.6)	49(45.4)	45(41.7)	63(58.3)
对照组	90	29.7±1.7	1 261±188	21(23.3)	27.5±1.8	42(46.7)	48(53.3)	46(51.1)	44(48.9)
检验值	?	t＝－1.380	t＝0.832	χ²＝3.296	t＝0.114	χ²＝1.246		χ²＝1.763
P值	?	0.169	0.407	0.069	0.910	0.264		0.184
组别	例数	母亲胎膜早破>18 h[例数(%)]	母亲产前使用抗菌药物[例数(%)]	窒息[例数(%)]	中心静脉置管[例数(%)]	机械通气治疗[例数(%)]	静脉营养时间[d，M(P₂₅～P₇₅)]	双胎[例数(%)]	动脉导管未闭[例数(%)]
观察组	108	41(38.3)	33(30.6)	64(59.3)	42(38.9)	35(32.4)	14.0(10.0～20.0)	39(36.1)	59(54.6)
对照组	90	43(47.8)	31(34.4)	59(65.6)	23(25.6)	13(14.4)	13.0(9.8～20.0)	38(42.2)	46(51.1)
检验值	?	χ²＝1.789	χ²＝2.739	χ²＝0.827	χ²＝3.958	χ²＝8.625	Z＝－0.730	χ²＝0.771	χ²＝0.244
P值	?	0.181	0.254	0.363	0.047	0.003	0.466	0.380	0.621

表2 2组患儿医院感染发生率比较[例数(%)]

组别	例数	医院感染总发生率	确诊败血症	临床败血症	VAP	尿路感染
观察组	108	23(21.3)	6(5.6)	14(13.0)	0(0)	3(2.8)
对照组	90	31(34.4)	6(6.7)	23(25.6)	2(2.2)	2(2.2)
χ²值	?	4.279	0.106	5.123	—^a	0
P值	?	0.039	0.744	0.024	0.205	1.000^b

表2 2组患儿医院感染发生率比较[例数(%)]

组别	例数	医院感染总发生率	确诊败血症	临床败血症	VAP	尿路感染
观察组	108	23(21.3)	6(5.6)	14(13.0)	0(0)	3(2.8)
对照组	90	31(34.4)	6(6.7)	23(25.6)	2(2.2)	2(2.2)
χ²值	?	4.279	0.106	5.123	—^a	0
P值	?	0.039	0.744	0.024	0.205	1.000^b

表3 2组患儿临床结局比较

组别	例数	住院时间(d, ±s)	出院时头围(cm, ±s)	出院时体重(g, ±s)	好转出院[例数(%)]
观察组	108	47.4±17.0	31.8±1.5	2 084±251	94(87.0)
对照组	90	47.3±16.1	32.0±1.3	2 086±249	85(94.4)
检验值	?	t＝－0.040	t＝0.691	t＝0.051	χ²＝3.105
P值	?	0.968	0.490	0.959	0.078

表3 2组患儿临床结局比较

组别	例数	住院时间(d, ±s)	出院时头围(cm, ±s)	出院时体重(g, ±s)	好转出院[例数(%)]
观察组	108	47.4±17.0	31.8±1.5	2 084±251	94(87.0)
对照组	90	47.3±16.1	32.0±1.3	2 086±249	85(94.4)
检验值	?	t＝－0.040	t＝0.691	t＝0.051	χ²＝3.105
P值	?	0.968	0.490	0.959	0.078

[1]	de Souza Rugolo LM, Bentlin MR, Mussi-Pinhata M, et al. Late-onset sepsis in very low birth weight infants: a Brazilian neonatal research network study[J]. J Trop Pediatr, 2014, 60(6): 415-421.
[2]	Hentges CR, Silveira RC, Procianoy RS, et al. Association of late-onset neonatal Sepsis with late neurodevelopment in the first two years of life of preterm infants with very low birth weight[J]. J Pediatr (Rio J), 2014, 90(1): 50-57.
[3]	Gephart SM, Weller M. Colostrum as oral immune therapy to promote neonatal health[J]. Adv Neonatal Care, 2014, 14(1): 44-51.
[4]	Thibeau S, Boudreaux C. Exploring the use of mothers′ own milk as oral care for mechanically ventilated very low-birth-weight preterm infants[J]. Adv Neonatal Care, 2013, 13(3): 190-197.
[5]	Lee J, Kim HS, Jung YH, et al. Oropharyngeal colostrum administration in extremely premature infants: an RCT[J]. Pediatrics, 2015, 135(2): e357-e366.
[6]	周勤，陶亚琴，李萍，等. 初乳口腔免疫治疗对极低出生体重儿临床预后影响的研究[J]. 中国儿童保健杂志，2018, 26(11): 1189-1193.
[7]	中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志，2001, 81(5): 314-320.
[8]	中华医学会儿科学分会新生儿学组，中华医学会《中华儿科杂志》编辑委员会. 新生儿败血症诊疗方案[J]. 中华儿科杂志，2003, 41(12): 897-899.
[9]	邵肖梅，叶鸿瑁，丘小汕. 实用新生儿学[M]. 4版. 北京：人民卫生出版社，2011: 405, 664.
[10]	de Luca D, Stronati M, Jacqz-Aigrain E, et al. Prevention of nosocomial infections in neonatal intensive care units[J]. Amer J Perinatol, 2013, 30(2): 81-88.
[11]	Chen YC, Lin CF, Rehn YF, et al. Reduced nosocomial infection rate in a neonatal intensive care unit during a 4-year surveillance period[J]. J Chin Med Assoc, 2017, 80(7): 427-431.
[12]	Cura C, Ozen M, Akaslan Kara A, et al. Health care-associated infection surveillance in a tertiary neonatal intensive care unit: A prospective clinical study after moving to a new building[J]. Am J Infect Control, 2016, 44(1): 80-84.
[13]	Li QF, Xu H, Ni XP, et al. Impact of relocation and environmental cleaning on reducing the incidence of healthcare-associated infection in NICU[J]. World J Pediatr, 2017, 13(3): 217-221.
[14]	Lee HC, Kurtin PS, Wight NE, et al. A quality improvement project to increase breast milk use in very low birth weight infants[J]. Pediatrics, 2012, 130(6): e1679-e1687.
[15]	Polin RA, Denson S, Brady MT, et al. Epidemiology and diagnosis of health care-associated infections in the NICU[J]. Pediatrics, 2012, 129(4): e1104-e1109.
[16]	Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments[J]. Arch Dis Child Fetal Neonatal Ed, 2015, 100(3): F257-F263.
[17]	Zhang YX, Ji FT, Hu XJ, et al. Oropharyngeal colostrum administration in very low birth weight infants: a randomized controlled trial[J]. Pediatr Crit Care Med, 2017, 18(9): 869-875.
[18]	Snyder R, Herdt A, Mejias-Cepeda N, et al. Early provision of oropharyngeal colostrum leads to sustained breast milk feedings in preterm infants[J]. Pediatr Neonatol, 2017, 58(6): 534-540.
[19]	Glass KM, Greecher CP, Doheny KK. Oropharyngeal administration of colostrum increases salivary secretory IgA levels in very low-birth-weight infants[J]. Am J Perinatol, 2017, 34(14): 1389-1395.
[20]	Nasuf AWA, Ojha S, Dorling J. Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants[J]. Cochrane Database Syst Rev, 2018, 9: CD011921.
[21]	Rodriguez NA, Vento M, Claud EC, et al. Oropharyngeal administration of mother′s colostrum, health outcomes of premature infants: study protocol for a randomized controlled trial[J]. Trials, 2015, 16: 453.
[22]	胡金梅. 口咽途径给予母乳对早产儿影响的研究进展[J]. 中华护理杂志，2017, 52(1): 107-110.
[23]	王娟，王勇兵，李凯，等. 新生儿重症监护室VAP的危险性因素分析及预防措施研究[J]. 临床肺科杂志，2019, 24(4): 714-716.
[24]	Mohseny AB, van Velze V, Steggerda SJ, et al. Late-onset sepsis due to urinary tract infection in very preterm neonates is not uncommon[J]. Eur J Pediatr, 2018, 177(1): 33-38.
[25]	Ruangkit C, Satpute A, Vogt BA, et al. Incidence and risk factors of urinary tract infection in very low birth weight infants[J]. J Neonatal Perinatal Med, 2016, 9(1): 83-90.
[26]	Levy I, Comarsca J, Davidovits M, et al. Urinary tract infection in preterm infants: the protective role of breastfeeding[J]. Pediatr Nephrol, 2009, 24(3): 527-531.
[27]	Rodriguez NA, Caplan MS. Oropharyngeal administration of mother′s milk to prevent necrotizing enterocolitis in extremely low-birth-weight infants: theoretical perspectives[J]. J Perinat Neonatal Nurs, 2015, 29(1): 81-90.

[1]	Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[2]	Meicen Zhou, Hua Wang, Dezhi Mu. Vaccination timeliness in preterm infants: a review of literature[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(03): 261-266.
[3]	Chenxi Li, Xiaorong Tan, Wei Wei, Muqiu Li, Zhongcheng Gong. Characteristics and significance of tertiary lymphoid structures in oral cancer[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 315-321.
[4]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[5]	Jia Yan, Shuangchi Liu, Zhengyu Wang. Progress in the research and application of tumor markers for gallbladder cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 391-394.
[6]	Yongting Xue, Feng Gao, Yanan Wang, Lianping Qu. Application of oncolytic virus therapy in colorectal cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 380-384.
[7]	Yujie Xu, Guodong Zhao. Advances and challenges in the treatment of advanced gastric cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 451-455.
[8]	Bitao Wang, Zheng Wang, Guobin Wang. Treatment status and progress of Lynch syndrome[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 332-335.
[9]	Kai Yan, Yong Fu, Zhengtao Zhang. Predictive model of therapeutic effect of middle and advanced liver cancer and research progress of organoid models of liver cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(03): 348-351.
[10]	Chen Cai, Wei Gong. Current application and outlook of immunotherapy for bile duct neoplasms[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(02): 162-166.
[11]	Runzhi Chen, Dongmei Yang, Huiting Xu. PD-1 combined with surufatinib for the treatment of metastatic colon cancer with microsatellite stability and BRAF V600E mutation: A case report and review[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 431-435.
[12]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[13]	Liu Yang, Lanqun Qin, Qian Geng, Dongqing Li, Chunjian Qi, Hua Jiang. Predictive value of efficacy and prognosis of soluble immune checkpoints for immunotherapy in patients with gastric cancer[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 305-311.
[14]	Meisha Fu, Yuhua Zhou, Hui Li, Chunyan Xue. Effect of lymphocyte immunotherapy on T lymphocyte subset distribution and PD1/PD-L1 expression in patients with recurrent miscarriage[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 726-730.
[15]	Qiyue Zhang, Xiaodong Wang. Progress in understanding of relationship between IL-8 and tumor immunity[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 605-613.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export